Your Health, We Care
Eltrombopag is the world's first small molecule non peptide thrombopoietin receptor (TPO-R) agonist approved by the US Food and Drug Administration (FDA). It was approved by the FDA in 2008 for the treatment of idiopathic thrombocytopenic purpura (ITP).
Eltrombopag, as the first approved small molecule non peptide TPO-R agonist, occupies an important position in the drug market. It, together with other similar products such as Avatrombopag and Lusutotrombopag, constitutes an important drug choice for the treatment of thrombocytopenia.
The immunotherapy drug Promacta (eltrombopag) has recently been granted an expan···【more】
Release date：2026-02-13Recommended：53
Severe Aplastic Anemia (SAA) is a relatively serious and rare blood disorder. If···【more】
Release date：2026-02-13Recommended：56
To explore the price of eltrombopag and its role in the treatment of specific di···【more】
Release date：2025-03-13Recommended：230
In the healthcare sector, the price of medicines is an aspect of great concern f···【more】
Release date：2025-03-13Recommended：258
Variety and availability of medications is an important consideration for both p···【more】
Release date：2025-03-12Recommended：231
Eltrombopag is a drug used to treat specific blood disorders, and its clinical a···【more】
Release date：2025-03-12Recommended：242
